ZA200110408B - Methods for treating diabetes. - Google Patents
Methods for treating diabetes.Info
- Publication number
- ZA200110408B ZA200110408B ZA200110408A ZA200110408A ZA200110408B ZA 200110408 B ZA200110408 B ZA 200110408B ZA 200110408 A ZA200110408 A ZA 200110408A ZA 200110408 A ZA200110408 A ZA 200110408A ZA 200110408 B ZA200110408 B ZA 200110408B
- Authority
- ZA
- South Africa
- Prior art keywords
- methods
- type
- diabetes
- symptoms
- treating diabetes
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 208000024891 symptom Diseases 0.000 abstract 3
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 abstract 2
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 abstract 2
- 206010022491 Insulin resistant diabetes Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/326,189 US6040292A (en) | 1999-06-04 | 1999-06-04 | Methods for treating diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200110408B true ZA200110408B (en) | 2003-03-19 |
Family
ID=23271175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200110408A ZA200110408B (en) | 1999-06-04 | 2001-12-19 | Methods for treating diabetes. |
Country Status (16)
Country | Link |
---|---|
US (1) | US6040292A (de) |
EP (1) | EP1183042B1 (de) |
JP (1) | JP2003501397A (de) |
KR (1) | KR100694737B1 (de) |
CN (1) | CN1235637C (de) |
AT (1) | ATE271880T1 (de) |
AU (1) | AU780400B2 (de) |
CA (1) | CA2373281C (de) |
DE (1) | DE60012517T2 (de) |
ES (1) | ES2222208T3 (de) |
HK (1) | HK1044895A1 (de) |
IL (1) | IL146868A0 (de) |
MX (1) | MXPA01013384A (de) |
NO (1) | NO324117B1 (de) |
WO (1) | WO2000074710A2 (de) |
ZA (1) | ZA200110408B (de) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6040292A (en) * | 1999-06-04 | 2000-03-21 | Celtrix Pharmaceuticals, Inc. | Methods for treating diabetes |
US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
DK1935427T3 (en) * | 2000-07-03 | 2018-06-06 | Bristol Myers Squibb Co | APPLICATIONS OF SOLUBLE, MUTANT CTLA4 MOLECULES |
AU9109001A (en) * | 2000-09-19 | 2002-04-02 | Bioexpertise Llc | Method for use of IGF-binding protein for selective sensitization of target cells in vivo |
US20040220190A1 (en) * | 2002-07-29 | 2004-11-04 | Cincotta Anthony H. | Methods of treating metabolic syndrome using dopamine receptor agonists |
US20040077679A1 (en) * | 2002-07-29 | 2004-04-22 | Cincotta Anthony H. | Therapeutic treatment for the metabolic syndrome and type 2 diabetes |
US9655865B2 (en) | 2002-07-29 | 2017-05-23 | Veroscience, Llc | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
US20080200453A1 (en) | 2002-07-29 | 2008-08-21 | Cincotta Anthony H | Methods of treating metabolic syndrome using dopamine receptor agonists |
US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
US20040081678A1 (en) * | 2002-08-09 | 2004-04-29 | Anthony Cincotta | Therapeutic process for the treatment of obesity and associated metabolic disorders |
US8137994B2 (en) * | 2004-03-25 | 2012-03-20 | Veroscience Llc | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
US20050215558A1 (en) * | 2004-03-25 | 2005-09-29 | Cincotta Anthony H | Methods of identifying responders to dopamine agonist therapy |
US8137993B2 (en) * | 2004-03-25 | 2012-03-20 | Veroscience Llc | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
CN101128124A (zh) * | 2004-12-30 | 2008-02-20 | 希尔氏宠物营养品公司 | 用于猫消费的组合物 |
JP5449134B2 (ja) * | 2007-04-18 | 2014-03-19 | プレーマクレ・アクチエボラーグ | 未熟児合併症の治療及び/又は予防の方法と製品 |
EP2352514A4 (de) * | 2008-10-29 | 2012-07-25 | Univ Rockefeller | Verfahren und kits zur krankheitsbehandlung durch verabreichung des einen insulinähnlichen wachstumsfaktor bindenden proteins 2 |
AR075998A1 (es) | 2009-04-01 | 2011-05-11 | Genentech Inc | Tratamiento de trastornos resistentes a insulina.composicion farmaceutica. uso. kit |
US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
US8575207B2 (en) | 2010-08-16 | 2013-11-05 | Allergan, Inc. | Method of activating regulatory T cells with alpha-2B adrenergic receptor agonists |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5200509A (en) * | 1987-04-06 | 1993-04-06 | Celtrix Pharmaceuticals, Inc. | Human somatomedin carrier protein subunits and process for producing them; recombinant DNA molecules, hosts, processes and human somatomedin carrier protein-like polypeptides |
US4988675A (en) * | 1988-02-05 | 1991-01-29 | Ciba-Geigy Corporation | Method for preventing secondary effects |
GB8920381D0 (en) * | 1989-09-08 | 1989-10-25 | Greater Glasgow Health Board | Treatment of insulin-resistant diabetes |
SE9201573D0 (sv) * | 1992-05-19 | 1992-05-19 | Kabi Pharmacia Ab | Use of igf-1 |
NZ255461A (en) * | 1992-08-20 | 1996-12-20 | Biotechnology & Biolog Science | Specific binding molecules for insulin-like-growth-factor-1 (igf-1), antigens capable of generating them and their use in enhancing igf-1 activity |
US5407913A (en) * | 1992-12-03 | 1995-04-18 | Celtrix Pharmaceuticals, Inc. | Method and composition for systemic treatment of tissue injury |
JPH08500123A (ja) * | 1993-01-25 | 1996-01-09 | ザ ベス イスラエル ホスピタル アソシエイション | Igf−i感受性細胞のバリヤー特性の修飾方法,診断方法及びスクリーニング方法 |
US5563046A (en) * | 1993-08-02 | 1996-10-08 | Celtrix Pharmaceuticals, Inc. | Fusion polypeptides and proteins |
ATE190499T1 (de) * | 1993-08-03 | 2000-04-15 | Celtrix Pharma | Methode zur behandlung von reproduktionserkrankungen |
ES2241906T3 (es) * | 1993-09-20 | 2005-11-01 | Celtrix Pharmaceuticals, Inc. | Tratamiento de trastornos inmunologicos y hematologicos con igfbp solo o asociado con igf. |
JPH09509140A (ja) * | 1993-11-15 | 1997-09-16 | セルトリックス ファーマシューティカルズ,インコーポレイテッド | 神経学的障害の治療方法 |
EP0732933B1 (de) * | 1993-11-15 | 2002-10-09 | Celtrix Pharmaceuticals, Inc. | Verwendung von igf-1 und igfbp-3 zur herstellung eines arzneimittels zur behandlung von einer nierenerkrankung |
JPH10512235A (ja) * | 1994-07-20 | 1998-11-24 | セルトリックス ファーマシューティカルズ,インコーポレイテッド | 骨形成の促進および骨再造形の調節のためのigf/igfbp複合体 |
US5741776A (en) * | 1995-05-22 | 1998-04-21 | Genentech, Inc. | Method of administration of IGF-I |
US6436897B2 (en) * | 1998-06-01 | 2002-08-20 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for IGF/IGFBP |
US6040292A (en) * | 1999-06-04 | 2000-03-21 | Celtrix Pharmaceuticals, Inc. | Methods for treating diabetes |
-
1999
- 1999-06-04 US US09/326,189 patent/US6040292A/en not_active Expired - Lifetime
-
2000
- 2000-05-23 WO PCT/US2000/014163 patent/WO2000074710A2/en active IP Right Grant
- 2000-05-23 JP JP2001501244A patent/JP2003501397A/ja active Pending
- 2000-05-23 DE DE60012517T patent/DE60012517T2/de not_active Expired - Lifetime
- 2000-05-23 ES ES00932729T patent/ES2222208T3/es not_active Expired - Lifetime
- 2000-05-23 AT AT00932729T patent/ATE271880T1/de active
- 2000-05-23 CN CNB008112649A patent/CN1235637C/zh not_active Expired - Fee Related
- 2000-05-23 CA CA002373281A patent/CA2373281C/en not_active Expired - Fee Related
- 2000-05-23 IL IL14686800A patent/IL146868A0/xx not_active IP Right Cessation
- 2000-05-23 MX MXPA01013384A patent/MXPA01013384A/es active IP Right Grant
- 2000-05-23 KR KR1020017015628A patent/KR100694737B1/ko not_active IP Right Cessation
- 2000-05-23 AU AU50411/00A patent/AU780400B2/en not_active Ceased
- 2000-05-23 EP EP00932729A patent/EP1183042B1/de not_active Expired - Lifetime
-
2001
- 2001-12-04 NO NO20015932A patent/NO324117B1/no not_active IP Right Cessation
- 2001-12-19 ZA ZA200110408A patent/ZA200110408B/xx unknown
-
2002
- 2002-09-02 HK HK02106479A patent/HK1044895A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU5041100A (en) | 2000-12-28 |
DE60012517D1 (de) | 2004-09-02 |
AU780400B2 (en) | 2005-03-17 |
CA2373281C (en) | 2010-01-12 |
NO20015932L (no) | 2002-01-31 |
IL146868A0 (en) | 2002-08-14 |
WO2000074710A2 (en) | 2000-12-14 |
CN1387440A (zh) | 2002-12-25 |
MXPA01013384A (es) | 2003-09-04 |
JP2003501397A (ja) | 2003-01-14 |
US6040292A (en) | 2000-03-21 |
HK1044895A1 (en) | 2002-11-08 |
NO324117B1 (no) | 2007-08-27 |
KR20020020723A (ko) | 2002-03-15 |
ES2222208T3 (es) | 2005-02-01 |
NO20015932D0 (no) | 2001-12-04 |
KR100694737B1 (ko) | 2007-03-14 |
WO2000074710A3 (en) | 2001-06-28 |
EP1183042A2 (de) | 2002-03-06 |
ATE271880T1 (de) | 2004-08-15 |
CA2373281A1 (en) | 2000-12-14 |
EP1183042B1 (de) | 2004-07-28 |
CN1235637C (zh) | 2006-01-11 |
DE60012517T2 (de) | 2005-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200110408B (en) | Methods for treating diabetes. | |
MXPA03007374A (es) | Metodos para tratar diabetes mellitus. | |
MXPA04001525A (es) | Analogos de peptido -1 similar al glucagon. | |
MY137350A (en) | Glucagon-like peptide-1 analogs | |
NZ504258A (en) | Exendin 3 and 4 agonist compounds for the treatment of diabetes | |
HK1022701A1 (en) | Exendin analogues, processes for their preparationand medicaments containing them exendin. | |
NO20010982L (no) | Fremgangsmåte for å administrere insulinotropiske peptider | |
SG127714A1 (en) | Method of treating metabolic disorders, especiallydiabetes, or a disease or condition associated wi th diabetes | |
MY132626A (en) | CARBAZOLYL-SUBSTITUTED ETHANOLAMINES AS SELECTIVE ß-3 AGONISTS | |
BR0308904A (pt) | Método de tratamento de gastroparesia, e, uso de um composto de glp-1 | |
SE9201573D0 (sv) | Use of igf-1 | |
BG104059A (en) | Diabetes treatment with rosiglytazone and insulin | |
WO1999053064A3 (en) | Methods of delivering glp-1 | |
WO1999051216A3 (en) | 3-pyridyloxyalkylamine or aryloxyalkylamine derivatives as cholinergic agonists | |
UA32255A (uk) | Спосіб лікування цукрового діабету | |
UA32295A (uk) | Спосіб лікування порушень фертильності у хворих на цукровий діабет | |
UA88862C2 (en) | Glucagon-like peptide-1 analogs | |
UA32254A (uk) | Спосіб лікування хронічного пієлонефриту у хворих на цукровий діабет | |
ECSP993116A (es) | Procedimiento para administrar peptidos insulinotropicos |